Examkin

Soru

Zorluk: Çok zorMenstrual Cycle Abnormalities and Contraception

Evaluate the following complex patient profiles. Match each clinical scenario with the single most appropriate, highly effective contraceptive method based on the WHO/CDC Medical Eligibility Criteria (MEC).

  • A 29-year-old woman with systemic lupus erythematosus and a history of deep vein thrombosis. Laboratory testing confirms the presence of lupus anticoagulant. She has regular, normal-volume menstrual periods.Copper-bearing intrauterine device
  • A 39-year-old woman who smokes 20 cigarettes daily. She is currently admitted to the hospital receiving intravenous antibiotics for an acute tubo-ovarian abscess.Etonogestrel subdermal implant
  • A 42-year-old woman with a blood pressure of 155/95 mmHg, severe heavy menstrual bleeding causing anemia, and a documented history of Wilson disease.Levonorgestrel-releasing intrauterine device
  • A 26-year-old woman with sickle cell disease and epilepsy managed with phenytoin. Pelvic ultrasound reveals a 5-cm submucosal leiomyoma significantly distorting the uterine cavity.Depot medroxyprogesterone acetate (intramuscular)

Cevap

The correct matches are: SLE/Antiphospholipid patient → Copper IUD; 39-year-old smoker with PID → Etonogestrel implant; Hypertensive with Wilson disease → Levonorgestrel IUD; Phenytoin user with distorted cavity → Depot medroxyprogesterone acetate.
Each clinical scenario requires the synthesis of at least two competing contraindications. The SLE patient with lupus anticoagulant requires a hormone-free method (Copper IUD) due to severe thrombophilia. The smoker with an active tubo-ovarian abscess cannot safely receive estrogen or an IUD, leaving the subdermal implant. The hypertensive patient with Wilson disease requires an LNG-IUD for medical management of bleeding while avoiding copper and estrogen. The patient on phenytoin with a distorted cavity requires DMPA to bypass both hepatic enzyme induction and anatomic constraints.

Adım Adım Çözüm

1
Evaluate the systemic lupus erythematosus (SLE) patient with antiphospholipid antibodies.
Identify that both estrogen (MEC 4) and progestin-only methods (MEC 3) are restricted due to severe thrombophilia risk.
This leaves the non-hormonal Copper IUD as the only highly effective, MEC 1 option.
2
Evaluate the 39-year-old smoker with active pelvic inflammatory disease (PID).
Identify that age >35 plus smoking >15 cigarettes/day contraindicates estrogen (MEC 4), and active PID contraindicates IUD initiation (MEC 4).
This leaves the etonogestrel subdermal implant as the optimal MEC 1 option.
3
Evaluate the hypertensive patient with heavy bleeding and Wilson disease.
Identify that hypertension contraindicates estrogen (MEC 3), while Wilson disease strictly contraindicates the Copper IUD (MEC 4).
The levonorgestrel IUD is MEC 1 for hypertension, treats the heavy menstrual bleeding, and contains no copper.
4
Evaluate the patient taking phenytoin with a distorted uterine cavity.
Identify that phenytoin (CYP450 inducer) reduces the efficacy of most systemic hormones (MEC 3), and a distorted cavity contraindicates all IUDs (MEC 4).
Depot medroxyprogesterone acetate (DMPA) bypasses hepatic enzyme induction to maintain efficacy and is unaffected by uterine anatomy.

Anahtar Kavram

Advanced application of the Medical Eligibility Criteria (MEC) for contraceptive use in patients with overlapping medical comorbidities, anatomic abnormalities, and drug interactions.
Tahmini Süre:2m 0s
Bu soruyu puanla

Konular

Menstrual Cycle Abnormalities and Contraception

Bu konudan daha fazla soru